Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-03-17
1997-04-15
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 31495
Patent
active
056209797
ABSTRACT:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal.
Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.
REFERENCES:
patent: 3962440 (1976-06-01), St. Clair et al.
patent: 3992378 (1976-11-01), St. Clair et al.
patent: 4312807 (1982-01-01), Fuchs
patent: 4659713 (1987-04-01), Hass
patent: 4803270 (1989-02-01), Takemoto
patent: 4812458 (1989-03-01), Honor e et al.
patent: 4889855 (1989-12-01), Jacobsen et al.
patent: 4912108 (1990-03-01), Jacobsen et al.
patent: 4948794 (1990-08-01), Honore et al.
patent: 4975430 (1990-12-01), Jahr et al.
patent: 4977155 (1990-12-01), Jacobsen et al.
patent: 4994460 (1991-02-01), Dextraze et al.
patent: 5026704 (1991-06-01), Honore et al.
patent: 5055465 (1991-10-01), Davey
patent: 5055470 (1991-10-01), Boissard et al.
patent: 5057516 (1991-10-01), Jacobsen et al.
patent: 5061706 (1991-10-01), Honore e et al.
patent: 5075306 (1991-12-01), Jacobsen et al.
patent: 5079250 (1992-01-01), Jacobsen et al.
patent: 5081123 (1992-01-01), Honor e et al.
patent: 5109001 (1992-04-01), Jacobsen et al.
patent: 5166155 (1992-11-01), Jorgensen et al.
patent: 5187171 (1993-02-01), Cordi
patent: 5190941 (1993-03-01), Nozulak et al.
patent: 5196421 (1993-03-01), McQuaid et al.
patent: 5198461 (1993-03-01), W atjen et al.
patent: 5268378 (1993-12-01), Baker et al.
patent: 5283244 (1994-02-01), Sakamoto et al.
patent: 5308845 (1994-05-01), Honor e et al.
patent: 5352683 (1994-10-01), Mayer et al.
Honor e et al., "Preparation and use of neuroleptic quinoxaline compounds," Chem. Abst. 114:81885q (1990).
Honor e et al., "Quinoxalinediones Non-N-Methyl-D-aspartate Receptor Antagonists as Potential Drug Candidates", pp. 451-460, in: Excitatory Amino Acids, Meldrum et al. (eds.), Raven Press Ltd., New York (1991).
Honor e et al., "Quinoxalinediones: Potent Competitive Non-NMDA Glutamate Receptor Antagonists", Science 241:701-703 (Aug. 5, 1988).
Frenk et al., "Absence of Side-Effects in the Anticonvulsant Action of Cortically Applied Antagonists of N-Methyl-D-Aspartate", Brain Res. 373:222-226 (1986).
Hays et al., "N-Sulfonyl Derivatives of 6,7-Dichloro 3,4-Dihydro-3-Oxo-quinoxalinecarboxylate as Glycine-site NMDA and AMPA Antagonists", Bioorg. & Med. Chem. Lett. 3:77-80 (Jan. 1993).
Honore et al., "Preparation and testing of 2,3 (1H, 4H)-- quinoxalinediones as neuroleptics," Chem. Abst. 111:232859a (1989).
Davies & Collingridge, "Quinoxalinediones as Excitatory Amino Acid Antagonists in the Vertebrate Central Nervous System", Int. Rev. Neurobiol. 32:281-303 (1990).
Drejer & Honor e, "New quinoxalinediones show potent antagonism of quisqualate responses in cultured mouse cortical neurons", Neur. Lett. 87:104-108 (1988).
Fletcher et al., "Quinoxalinediones selectively block quisqualate and Kainate receptors and synaptic events in rat neocortex and hippocampus and frog spinal cord in vitro", Br. J. Pharmacol. 95:585-597 (1988).
Carling et al., "Anticonvulsant Activity of Glycine-site NMDA Antagonists", Bioorganic & Medicinal Chem. Lett. 3:65-70 (Jan. 1993).
Carling et al., "3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory Amino Acid Antagonists Acting at Glycine-Site NMDA and (RS) -.alpha.-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors", J. Med. Chem. 36:3397-3408 (Oct. 1993).
Cheeseman, G. W. H., "Quinoxalines and Related Compounds, Part VI. Substitution of 2,3-Dihydroxyquinoxaline and its 1,4-Dimethyl Derivative", J. Chem. Soc. 223:1170-1176 (1962).
Adreasen et al., "Effects of Non-N-Methyl-D-Aspartate Antagonists on Synaptic Transmission in the In Vitro Rat Hippocampus", J. Physiol. 414:317-336 (1989).
Bigge, C., "Structural Requirements for the Development of Potent N-Methyl-D-Aspartic Acid (NMDA) Receptor Antagonists", Biochem. Pharm. 45:1547-1561 (Apr. 1993).
Birch et al., "FG-9065 and FG-9041 antagonise responses to NMDA via an action at the strychnine-insensitive glycine receptor", Meeting of the British Pharmacological Society, Nottingham, England, Sep. 7-9, 1988, Br. J. Pharmacol. 95:758P (1988).
Yamada et al., "Quantitative Physiological Characterization of a Quinoxalinedione non-NMDA Receptor Antagonist", J. Neurosci. 9:3230-3236 (Sep. 1989).
Yoneda & Ogita, "Abolition of the NMDA-Mediated Responses by a Specific Glycine Antagonist, 6,7-Dichloroquinoxaline-2,3-Dione (DCOX)", Biochem. & Biophys. Res. Comm. 164:841-849 (Oct. 31, 1989).
Vaccarino et al., "NMDA Receptor Antagonists, MK-801 and ACEA-1011, Prevent the Development of Chronic Pain Following Subcutaneous Formalin," Brain Research 615:331-334 (Jul. 2, 1993).
Warner et al., "Glycine NMDA Receptor Antagonists Reduce Focal But Not Global Ischemic Brain Damage in the Rat," Soc. Neurosci. Abs. 19:1646, Abstract No. 674.3 (Nov. 1993).
White et al., "Anticonvulsant Profile and Therapeutic Potential of N-Methyl-D-Aspartic Acid and Strychnine-Insensitive Glycine Antagonists," Epilepsia 32. Suppl. 3:12 (Dec., 1991).
Horner et al., "Derivatives of quinoxaline as isosteres of the pteridines", Chem. Abst. 48:2692 (1953).
Joergensen et al., "Preparation of 1-carboxyalkyl-2,3-dioxoguinoxalines as glycine antagonists," Chem. Abst. 115:280059u (Dec., 1991).
Jurson & Freed, "A Slight Anticonvulsant Effect of CNQX and DNQX as measured by Homocysteine- and Quisqualate-Induced Seizures," Pharmacol. Biochem. Behav. 36:177-81 (1990).
Kay & Ikeda, "The quinoxalinediones antagonise the visual firing of sustained retinal ganglion cells", Eur. J. Pharmacol. 164:381-384 (1989).
Kehne et al., "NMDA Receptor Complex Antagonists have Potential Anxiolytic Effects as Measured with Separation-Induced Ultrasonic Vocalization," Eur. J. Pharmacol. 193:283-92 (Feb., 1991).
Kemp & Leeson, "The glycine site of the NMDA receptor-five years on", TiPS 14:20-25 (Jan. 1993).
Kessler et al., "A Glycine Site Associated with N-Methyl-D-Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists", J. Neurochem. 52:1319-1328 (1989).
Kessler et al., "Quinoxaline derivatives are high-affinity antagonists of the NMDA receptor-associated glycine sites", Brain Res. 489:377-382 (1989).
Kleckner & Dingledine, "Selectivity of Quinoxalines and Kynurenines as Antagonists of the Glycine Site on N-Methyl-D-aspartate Receptors", Mol. Pharmacol. 36:430-436 (1989).
Kulagowski et al., "3'-(Arylmethyl)-and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor," J. Med. Chem 37:1402-1405 (May 1994).
Leeson and Iversen, "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential," J. Med. Chem. 37:4053-4067 (Nov. 1994).
Leeson et al., "Amino Acid Bioisosteres: Design of 2-Quinolone Derivatives as Glycine-Site N-Methyl-D-asparatate Receptor Antagonists", Bioorg. & Med. Chem. Lett. 3:299-304 (Mar. 1993).
Leeson et al., "Kynurenic Acid Derivatives. Structure-Activity Relationships for Excitatory Amino Acid Antagonism and Identification of Potent and Selective Antagonists at the Glycine Site on the N-Methyl-D-aspartate Receptor", J. Med. Chem. 34:1243-1252 (Apr., 1991).
Leeson, P., "Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists", pp. 339-381, in: Drug Design for Neurosci., Kozikowski (ed.), Raven Press Ltd., New York (1993).
Lester et al., "Interaction of 6-Cyano-7-nitroquinoxaline-2,3-dione with the N-Methyl-D-aspartate Receptor-Associated Glycine Binding Site", Mol.
Keana John F. W.
Weber Eckard
Cebulak Mary C.
Dees Jos,e G.
State of Oregon, Acting By and Through The Oregon State Board of
The Regents of the University of California
LandOfFree
Glycine receptor antagonists and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycine receptor antagonists and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycine receptor antagonists and the use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-360954